Abiopharma

🔍 TAYLOR GLEN A (Director)

Company: Envoy Medical, Inc. (COCH)

Report Date: 2025-09-04

Detailed Transactions and Holdings:

• Holds 0 shares of Class A Common Stock (Direct)
  Date: 2025-09-04 | Code: H | shares_owned_after: 2,953,607.00
• Holds 0 shares of Class A Common Stock (Direct)
  Date: 2025-09-04 | Code: H | nature_of_ownership: By Taylor Sports Group | shares_owned_after: 2,526,058.00 | Footnotes: F1
• Holds 0 shares of Class A Common Stock (Direct)
  Date: 2025-09-04 | Code: H | nature_of_ownership: By GAT Funding, LLC | shares_owned_after: 4,810,384.00 | Footnotes: F2
• Sold 500,000 shares of Warrant (right to buy) at $1.24 per share (Derivative)
  Date: 2025-09-04 | Code: D | Expires: 2026-02-27 | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F4, F4, F5, F2
• Acquired 500,000 shares of Warrant (right to buy) at $1.24 per share (Derivative)
  Date: 2025-09-04 | Code: A | Expires: 2028-12-31 | equity_swap_involved: 0 | shares_owned_after: 500,000.00 | transaction_form_type: 4 | Footnotes: F4, F4, F5, F2
• Sold 250,000 shares of Warrant (right to buy) at $3.04 per share (Derivative)
  Date: 2025-09-04 | Code: D | Expires: 2026-02-27 | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F6, F6, F5, F2
• Acquired 250,000 shares of Warrant (right to buy) at $3.04 per share (Derivative)
  Date: 2025-09-04 | Code: A | Expires: 2028-12-31 | equity_swap_involved: 0 | shares_owned_after: 250,000.00 | transaction_form_type: 4 | Footnotes: F6, F6, F5, F2
• Sold 250,000 shares of Warrant (right to buy) at $2.25 per share (Derivative)
  Date: 2025-09-04 | Code: D | Expires: 2026-02-27 | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F7, F7, F5, F2
• Acquired 250,000 shares of Warrant (right to buy) at $2.25 per share (Derivative)
  Date: 2025-09-04 | Code: A | Expires: 2028-12-31 | equity_swap_involved: 0 | shares_owned_after: 250,000.00 | transaction_form_type: 4 | Footnotes: F7, F7, F5, F2
• Sold 500,000 shares of Warrant (right to buy) at $2.97 per share (Derivative)
  Date: 2025-09-04 | Code: D | Expires: 2026-08-27 | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F8, F8, F5, F2
• Acquired 500,000 shares of Warrant (right to buy) at $2.97 per share (Derivative)
  Date: 2025-09-04 | Code: A | Expires: 2028-12-31 | equity_swap_involved: 0 | shares_owned_after: 500,000.00 | transaction_form_type: 4 | Footnotes: F8, F8, F5, F2
• Sold 500,000 shares of Warrant (right to buy) at $2.2 per share (Derivative)
  Date: 2025-09-04 | Code: D | Expires: 2026-08-27 | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F9, F9, F5, F2
• Acquired 500,000 shares of Warrant (right to buy) at $2.2 per share (Derivative)
  Date: 2025-09-04 | Code: A | Expires: 2028-12-31 | equity_swap_involved: 0 | shares_owned_after: 500,000.00 | transaction_form_type: 4 | Footnotes: F9, F9, F5, F2
• Sold 750,000 shares of Warrant (right to buy) at $1.35 per share (Derivative)
  Date: 2025-09-04 | Code: D | Expires: 2028-03-11 | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F10, F10, F5, F2
• Acquired 750,000 shares of Warrant (right to buy) at $1.35 per share (Derivative)
  Date: 2025-09-04 | Code: A | Expires: 2028-12-31 | equity_swap_involved: 0 | shares_owned_after: 750,000.00 | transaction_form_type: 4 | Footnotes: F10, F10, F5, F2
• Sold 750,000 shares of Warrant (right to buy) at $1.48 per share (Derivative)
  Date: 2025-09-04 | Code: D | Expires: 2027-06-26 | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F11, F11, F5, F2
• Acquired 750,000 shares of Warrant (right to buy) at $1.48 per share (Derivative)
  Date: 2025-09-04 | Code: A | Expires: 2028-12-31 | equity_swap_involved: 0 | shares_owned_after: 750,000.00 | transaction_form_type: 4 | Footnotes: F11, F11, F5, F2
• Holds 869,565 shares of Series A Preferred Stock at $11.5 per share (Derivative)
  Date: 2025-09-04 | Code: H | shares_owned_after: 1,000,000.00 | Footnotes: F3, F3, F2

Footnotes:

• F1: The Reporting Person is the owner and chairman of Taylor Sports Group.
• F2: GAT Funding, LLC is an entity controlled by the Reporting Person.
• F3: Fully exercisable and there is no expiration date.
• F4: The two reported transactions involved an amendment of an outstanding warrant, resulting in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally purchased on 2/27/2024 and is fully exercisable.
• F5: Fully exercisable.
• F6: The two reported transactions involved an amendment of an outstanding warrant, resulting in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally granted on 5/23/2024 and is fully exercisable.
• F7: The two reported transactions involved an amendment of an outstanding warrant, resulting in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally granted on 7/22/2024 and is fully exercisable.
• F8: The two reported transactions involved an amendment of an outstanding warrant, resulting in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally granted on 8/27/2024 and is fully exercisable.
• F9: The two reported transactions involved an amendment of an outstanding warrant, resulting in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally granted on 12/11/2024 and is fully exercisable.
• F10: The two reported transactions involved an amendment of an outstanding warrant, resulting in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally granted on 3/11/2025 and is fully exercisable.
• F11: The two reported transactions involved an amendment of an outstanding warrant, resulting in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally granted on 6/26/2025 and is fully exercisable.